Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Has announcements × larotrectinib × Other solid neoplasm × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1 Thoracic 1 Sarcoma 1 Other solid neoplasm 1 Head & Neck 1 Gastrointestinal 1 Dermatologic 1 Breast 1

Conditions

Solid Tumors Harboring NTRK Fusion 1

Interventions

Nivolumab 3 Ipilimumab 3 pembrolizumab 2 entrectinib 2 cobimetinib 2 Pemetrexed 2 Cisplatin 2 tovorafenib 1 sotorasib 1 relatlimab 1 pralsetinib 1 larotrectinib 1 ipatasertib 1 inavolisib 1 daratumumab 1 atezolizumab 1 alectinib 1 PM 01183 1 Midazolam 1 Carboplatin 1 Ado-Trastuzumab Emtansine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02122913 2026-02-05

A Study to Test the Safety of the Investigational Drug Larotrectinib in Adults That May Treat Cancer

Bayer

Phase 1 Completed

75 enrolled 3 FDA

Other solid neoplasm

Solid Tumors Harboring NTRK Fusion

Data powered by HemOnc (CC BY 4.0) Colophon ⚡